ArticleNeurosurgical review2025
Efficacy and safety of stereotactic radiosurgery for large cystic brain metastases: a comparison with and without cyst aspiration via Ommaya reservoir.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Radiotherapy for Refractory Cystic Progression in Basal Ganglia Pilocytic Astrocytoma: A Case Report.Cureus · 2026Article
- Catheter-tract recurrence after Ommaya reservoir-assisted cyst decompression followed by stereotactic radiosurgery for cystic brain metastasis: A case report.Surgical neurology international · 2026Article
- Systemic immune-inflammation index as a prognostic biomarker to predict overall survival after primary stereotactic radiosurgery for brain metastases.Journal of neuro-oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the therapeutic efficacy and safety of stereotactic radiosurgery (SRS) in the management of large cystic brain metastases. A retrospective analysis was conducted. Large cystic brain metastases were defined as cyst volume ≥ 5 mL. Tumors that received SRS as adjuvant therapy following surgery were excluded. The cohort was stratified into two groups: (1) SRS group (upfront hypofractionated SRS without Ommaya reservoir [OR]), (2) OR-SRS group (cyst aspiration via OR before SRS). Local tumor control rate (LCR), progression-free survival (PFS), overall survival (OS), and radiation-induced adverse events (RAEs) were evaluated. Thirty-one metastases in 28 patients met the inclusion criteria: SRS (14 metastases) and OR-SRS (17 metastases). Most baseline characteristics, including cyst diameter (P = 0.15), cyst volume (P = 0.06), and tumor volume (P = 0.95), were not significantly different between the groups. The cyst volume just before SRS in the OR-SRS group was significantly smaller compared to the SRS group (P < 0.01; Mann-Whitney U test). The LCR was 86% in the SRS group and 82% OR-SRS group (P = 1.00). Other outcomes, including PFS, RAEs, and OS, were not significantly different between the groups. Kaplan-Meier analysis revealed no statistically significant differences in PFS or OS among the groups (P = 0.28 and P = 0.20, respectively; log-rank test). This study demonstrates that both SRS and OR-SRS are effective and safe treatment modalities for large cystic brain metastases. The treatment outcomes were comparable, and these approaches may be equally viable options in the management of this challenging subset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.